{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:16:05Z","timestamp":1784614565096,"version":"3.55.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,16]]},"DOI":"10.1093\/ibd\/izy102","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T19:24:09Z","timestamp":1523561049000},"page":"2053-2061","source":"Crossref","is-referenced-by-count":52,"title":["Nonadherence to Biologic Therapies in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Brian J","family":"Wentworth","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross C D","family":"Buerlein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G","family":"Tuskey","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Ashley","family":"Overby","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Smolkin","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W","family":"Behm","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"key\n\t\t\t\t20180816113431_CIT0001","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180816113431_CIT0002","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2009.02.001","article-title":"Biological therapies for inflammatory bowel diseases","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180816113431_CIT0003","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1365-2036.2006.03092.x","article-title":"Adherence rates with infliximab therapy in crohn\u2019s disease","volume":"24","author":"Kane","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180816113431_CIT0004","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/MIB.0b013e31829ed8a6","article-title":"Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease","volume":"19","author":"Selinger","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180816113431_CIT0005","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","article-title":"Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180816113431_CIT0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ibd.21491","article-title":"Adherence to adalimumab therapy in crohn\u2019s disease: a french multicenter experience","volume":"17","author":"Billioud","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180816113431_CIT0007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/CGast.S7613","article-title":"Patient adherence and efficacy of certolizumab pegol in the management of crohn\u2019s disease","volume":"5","author":"Blonski","year":"2012","journal-title":"Clin Med Insights Gastroenterol"},{"key":"key\n\t\t\t\t20180816113431_CIT0008","first-page":"S26","article-title":"Adherence rates with certolizumab pegol therapy: Results from a retrospective analysis of patient claims data","volume":"23","author":"Wolf","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180816113431_CIT0009","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00005650-198808000-00007","article-title":"A general method of compliance assessment using centralized pharmacy records. Description and validation","volume":"26","author":"Steiner","year":"1988","journal-title":"Med Care"},{"key":"key\n\t\t\t\t20180816113431_CIT0010","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1097\/MIB.0000000000000581","article-title":"Treatment nonadherence in inflammatory bowel disease: identification, scope, and management strategies","volume":"21","author":"Herman","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180816113431_CIT0011","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ecco-jcc\/jjw002","article-title":"Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study","volume":"10","author":"van der Have","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180816113431_CIT0012","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s12325-009-0069-7","article-title":"Adherence to infliximab maintenance therapy and health care utilization and costs by crohn\u2019s disease patients","volume":"26","author":"Kane","year":"2009","journal-title":"Adv Ther"},{"key":"key\n\t\t\t\t20180816113431_CIT0013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/9\/2053\/25502311\/izy102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:08:09Z","timestamp":1571141289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/9\/2053\/4969742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,4,13]]},"published-print":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy102","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,4,13]]}}}